Komori
Takara Bio (4974) · PolicyFirst stated

Regular Review of WACC, ROE, Share Price and PBR

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Enhancing Capital Efficiency and Shareholder Returns with an Awareness of Cost of Capital and Share PriceA theme 106 companies write about · 1 as a headwind · 106 as a tailwind

The whole theme swung hardest in 2020: 1 of 12 companies on the "Worse" side.

12 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 106 companies compared. The sentences above are computed from all 106.
Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「The Company regularly reviews WACC (weighted average cost of capital), ROE (return on equity), its share price and PBR (price-to-book ratio) at Board meetings, and practices management with awareness of capital costs and share price by seeking to improve capital efficiency over the medium to long term through profit growth and appropriate shareholder returns.」

    First independently stated a policy of regularly reviewing WACC, ROE, share price and PBR at Board meetings and improving capital efficiency through profit growth and shareholder returns.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Takara Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Regular Review of WACC, ROE, Share Price and PBR | TAKARA BIO INC. (4974) | Komori